



## External Quality Assessment Program for Multiple Respiratory Virus nucleic acid detection

Labquality is announcing a new EQA scheme Multiple Respiratory Virus nucleic acid detection (MultiRespVirus) for four respiratory viruses: SARS-CoV-2, Influenza A, Influenza B and RSV.

Each round will include three samples that should be analysed as regular patient samples. The participants submit their results through the electronic platform LabScala and results are processed by the EQA Coordinator. Result evaluations including comments by the Scheme Expert will be published in the final report distributed to the participants.

Round 1, 2021 will be conducted in November. Three rounds will be arranged in 2022 (February, June, November). All viruses will be included in the scheme during one calendar year starting in 2022.

### 5562 Multiple Respiratory Virus nucleic acid detection

**Samples:** 3 swab samples (non-infectious)

**Distribution:** 1, 2021 November. Three rounds will be conducted in 2022.

**Registration:** Please register by **August 30th, 2021** in LabScala or through your local distributor

### For more information

Labquality's customer service [info@labquality.fi](mailto:info@labquality.fi) or

**Heidi Berghäll**

Development Manager

[heidi.berghall@labquality.fi](mailto:heidi.berghall@labquality.fi)

+358 50 356 0503

**Marsa Järvenpää**

EQA Coordinator

[marsa.jarvenpaa@labquality.fi](mailto:marsa.jarvenpaa@labquality.fi)

+358 40 846 5166